西藏奇正藏药股份有限公司 2024 年第一季度报告 3 | --- | --- | --- | --- | --- | --- | --- | |---------------------------------|----------------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------ ...

一、本次股东大会的召集、召开程序 股东大会法律意见书 北京海润天睿律师事务所 关于西藏奇正藏药股份有限公司 2024 年第三次临时股东大会的法律意见书 致：西藏奇正藏药股份有限公司 北京海润天睿律师事务所（以下简称本所）接受西藏奇正藏药股份有限公司 （以下简称公司）的委托，指派律师吴团结、赵沁妍出席公司 2024 年第三次临 时股东大会并对本次股东大会进行律师见证。 本所律师依据《中华人民共和国公司法》（以下简称《公司法》）、《上市 公司股东大会规则》（以下简称《股东大会规则》）等法律法规、规范性文件及 《公司章程》的有关规定，就公司本次股东大会的召集、召开程序、出席会议人 员的资格、召集人资格、表决方式、表决程序及表决结果等事宜出具本法律意见 书。 经本所律师审查，公司董事会关于召开本次股东大会的通知已于 2024 年 4 月 11 日刊登于《证券时报》及深圳证券交易所、巨潮资讯网网站。通知中载明 了会议召开基本情况、会议审议事项、会议登记等事项、参加网络投票的具体操 作流程、备查文件等事项。 本次股东大会采用现场投票与网络投票相结合的方式。网络投票时间：2024 年 4 月 26 日，其中，通过深圳证券交 ...

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2024-030 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 2024 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会无否决或修改议案的情况； 2、本次股东大会不涉及变更前次股东大会决议的情况。 一、会议召开情况和出席情况 1、会议召集人：西藏奇正藏药股份有限公司（以下简称"公司"）第五届董 事会； 2、表决方式：现场投票与网络投票相结合方式； 3、会议时间 3.1 现场会议时间：2024年4月26日（星期五）下午14:30； 3.2 网络投票时间：2024年4月26日，其中，通过深圳证券交易所交易系统 进行网络投票的时间为2024年4月26日9:15－9:25、9:30－11:30、13:00－15:00； 通过深圳证券交易所互联网投票系统投票的时间为2024年4月26日9:15－15:00。 4、现场会议召开地点：北京市朝阳区望京北路9号叶青大厦D座 ...

| 证券代码：002287 | 证券简称：奇正藏药 公告编号：2024-034 | | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | 西藏奇正藏药股份有限公司 第六届监事会第一次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 1、西藏奇正藏药股份有限公司（以下简称"公司"）第六届监事会第一次会 议于 2024 年 4 月 26 日以现场形式在公司会议室召开； 1、审议通过了《关于选举公司第六届监事会主席的议案》。 选举王志强先生为公司第六届监事会主席，任期自本次会议审议通过之日起 至第六届监事会任期届满时止。王志强先生简历详见2024年4月27日刊登在《证 券时报》、巨潮资讯网（http://www.cninfo.com.cn）上的《关于选举职工代表 监事的公告》（公告编号：2024-032）。 （表决票 5 票，5 票同意、0 票反对、0 票弃权） 三、备查文件 1、经与会监事签字并加盖监事会印章的监事会决议。 特此公告 2、本次会议豁免通知时限要求，2024 年 4 月 26 日公司 202 ...

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2024-031 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 董事会 二○二四年四月二十七日 西藏奇正藏药股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏奇正藏药股份有限公司（以下简称"公司"）第五届董事会任期即将届 满，为保证公司董事会的正常运作，根据《公司法》和《公司章程》的有关规定， 公司于 2024 年 4 月 26 日召开职工代表大会，经与会职工审议，选举桑杰东主先 生为公司第六届董事会职工代表董事。职工代表董事简历详见附件一。 桑杰东主先生与 2024 年第三次临时股东大会选举产生的 3 名非独立董事、 3 名独立董事共同组成公司第六届董事会，任期三年，与股东大会选举产生的第 六届董事会非独立董事、独立董事的任期相同。 本次选举 1 名职工代表董事后，董事会中兼任公司高级管理人员以及由职工 代表担任的董事人数总计未超过公司董事总数的二分之一。 特此公告 ...

| 证券代码：002287 | 证券简称：奇正藏药 公告编号：2024-032 | | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | 西藏奇正藏药股份有限公司 关于选举职工代表监事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏奇正藏药股份有限公司（以下简称"公司"）第五届监事会任期即将届 满，为保证公司监事会的正常运作，根据《公司法》和《公司章程》的有关规定， 公司于 2024 年 4 月 26 日召开职工代表大会，经与会职工审议，选举王志强先 生、白玛仓决女士、王艺睿女士、陈宏艳女士为公司第六届监事会职工代表监事。 职工代表监事简历详见附件一。 截至目前，白玛仓决女士未持有公司股份；未在公司 5%以上股东、控股股东 等单位任职；与持有公司 5%以上股份的股东、实际控制人、公司其他董事、监 事、高级管理人员不存在关联关系。白玛仓决女士不存在以下情形：（1）受过中 国证监会及其他有关部门的处罚和证券交易所纪律处分，因涉嫌犯罪被司法机关 立案侦查或者涉嫌违法违规被中国证监会立案稽查，尚未有明确结论；（2）曾被 中国证 ...

2、本次会议豁免通知时限要求，2024 年 4 月 26 日公司 2024 年第三次临时 股东大会、职工代表大会选举产生第六届董事会成员后，以口头方式向所有董事、 监事及高级管理人员送达了会议通知； 3、会议应参加表决董事 7 人，实际参加表决董事 7 人，其中独立董事 3 名， 公司监事及高级管理人员列席了会议； 4、经与会董事一致同意，推举董事刘凯列先生主持本次会议； | 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2024-033 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、西藏奇正藏药股份有限公司（以下简称"公司"）第六届董事会第一次会 议于 2024 年 4 月 26 日以现场形式在公司会议室召开； 5、本次会议的出席人数、召集召开程序、议事内容符合《公司法》和《公 司章程》的相关规定。 二、董事会会议审议情况 1、审议通过了《关于聘任公司名 ...

西藏奇正藏药股份有限公司 关于聘任公司名誉董事长的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 西藏奇正藏药股份有限公司（以下简称"公司"、"奇正藏药"）第六届董 事会第一次会议审议通过了《关于聘任公司名誉董事长的议案》，同意聘任雷菊 芳女士为公司名誉董事长。 | 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2024-035 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 自公司上市以来，雷菊芳女士担任公司第一届至第五届董事会董事长，以战 略思维构建公司基业常青的可持续发展体系；以对行业和社会的使命感和责任 感，带领公司不断突破创新，推动藏药产业现代化发展。雷菊芳女士推动公司积 极承担企业社会责任，参与公益事业，努力回馈社会，赢得了广泛的行业美誉和 社会认可。 公司董事会对雷菊芳女士履职期间为公司发展所做出的突出贡献表示诚挚 感谢，聘任雷菊芳女士为公司名誉董事长。"名誉董事长"是公司表达敬意和尊 重的最高荣誉称号，不享有董事的权利，也不承担董事的责任和义务。雷菊芳女 士仍为公司实 ...

2023 暨环境、社会及 公司治理（ESG）报告 微信扫码，即可订阅 "奇正藏药投资者关系平台"公众号 种 / 下 / 幸 / 福 获 / 取 / 自 / 在 | 董事长致辞 | 01 | 总裁致辞 | 02 | | | | --- | --- | --- | --- | --- | --- | | 01 | | 02 | | 03 | | | 责任管理 | 03 | 患者关爱 | 14 | 科技创新 | 21 | | 1.1 关于我们 | 04 | 2.1 丰富的药品选择 | 15 | 3.1 研发驱动 释放创新活力 | 22 | | 1.2 可持续发展管理 | 06 | 2.2 保证良药品质 筑牢品牌基石 | 17 | 3.2 打造医药制造力标杆 | 25 | | 1.3 责任实践 | 09 | | | 3.3 推动藏药产业发展 | 28 | | 1.4 公司治理 | 12 | | | | | | 04 | | 05 | | 06 | | | 员工发展 | 29 | 文化传承 | 37 | 资源保护 | 43 | | 4.1 有尊严地工作与生活 | 30 | 5.1 藏医药文化的保护与传承 | 38 | ...

Financial Performance - The total revenue for 2023 reached ¥2,045,152,409.09, a slight increase of 0.02% compared to ¥2,044,789,340.21 in 2022[47]. - The pharmaceutical segment generated ¥2,025,557,050.83, accounting for 99.04% of total revenue, showing a decrease of 0.25% from ¥2,030,566,606.22 in the previous year[47]. - The sales of patch products amounted to ¥1,422,840,597.33, representing 69.57% of total revenue, with a growth of 0.50% from ¥1,415,810,507.68[47]. - The net profit for the reporting period was CNY 579.18 million, with a significant difference of CNY 114.23 million from the net cash flow from operating activities, mainly due to depreciation, amortization, and impairment provisions[116]. - The net profit attributable to shareholders for 2023 was CNY 581,198,850.1, marking a significant increase of 22.99% from CNY 472,408,229 in 2022[198]. - The net cash flow from operating activities for 2023 was CNY 693,405,084.34, a substantial increase of 142.72% compared to CNY 285,686,729.21 in 2022[198]. - Basic earnings per share for 2023 were CNY 1.0972, up 22.98% from CNY 0.8919 in 2022[198]. - The total assets at the end of 2023 amounted to CNY 6,298,478,593.58, reflecting a growth of 6.97% from CNY 5,886,644,252.44 at the end of 2022[198]. - The net assets attributable to shareholders increased to CNY 3,720,328,772.46, an increase of 11.52% from CNY 3,336,014,084.43 in 2022[198]. - The company reported a quarterly breakdown of revenue, with Q4 2023 revenue at CNY 798,915,643.15, showing strong performance in the last quarter[199]. - The net profit attributable to shareholders in Q4 2023 was CNY 200,694,089.42, indicating robust profitability in the final quarter[199]. Research and Development - The company has established a comprehensive R&D platform to enhance the development of Tibetan medicine, emphasizing clinical value and sustainable resource development[28]. - The company is committed to enhancing its R&D quality system while improving the speed of development to maintain its leading position in Tibetan medicine research[34]. - The company has seen a growing demand for its products due to the aging population and increasing chronic disease prevalence in China[23]. - The company has made progress in new drug research, including the completion of clinical studies for various products such as the white ointment and pain relief aerosol[41]. - The company’s R&D personnel increased by 2.08% to 294, with the proportion of R&D personnel to total staff at 9.51%[80]. - Research and development expenses for the period were CNY 99.40 million, an increase of 14.86% from CNY 86.54 million in the previous year, accounting for 4.86% of operating revenue[113]. - The company is actively collaborating with domestic and international research institutions to advance new technologies and materials in product development[28]. - The company has a strong emphasis on R&D, continuously developing new products with clinical value based on traditional Tibetan medicine[58]. Market Position and Strategy - The company has a strong market position in the external pain relief sector, aiming to maintain its leadership in the Tibetan medicine market and external pain relief products[30]. - The company is focusing on the chronic disease market, particularly in areas such as bone diseases, tumors, and cardiovascular health, driven by the increasing healthcare consumption market in China[21]. - The company aims to become the leading brand in the external pain relief market through a comprehensive product solution strategy[61]. - The company has integrated its existing recruitment departments to accelerate market expansion and enhance sales capabilities[47]. - The company has implemented a strategy to strengthen its marketing capabilities across various channels, including medical, retail, and B2C sales[37]. - The company is focusing on expanding its product line across seven therapeutic areas, including respiratory, dermatology, pediatrics, gynecology, digestion, cardiovascular, and neurology[61]. - The company has established a self-marketing model and is expanding its retail channels, focusing on digital transformation and e-commerce growth[57]. - The company plans to enhance its marketing capabilities through academic and brand marketing, focusing on product development, channel expansion, and customer management[138]. - The company aims to expand its market presence by optimizing its marketing strategies and entering mainstream markets and retail pharmacies[182]. Investments and Financial Management - The total investment during the reporting period was CNY 1.49 billion, representing a year-on-year increase of 5.25% compared to CNY 1.42 billion in the same period last year[102]. - The cash flow from investment activities showed a net outflow of ¥310,590,606.06, a decrease of 7.15% from the previous year[82]. - The company raised a total of 451.20 million CNY in funds, with a commitment to invest 520.47 million CNY, resulting in a difference of 6.93 million CNY primarily due to interest income and cash management gains[132]. - The company utilized 36.40 million CNY of the raised funds during the reporting period, with a remaining balance of 2.01 million CNY stored in the dedicated fund account[131]. - The company has established a new subsidiary, Tibet Yuzheng Medicinal Materials Co., Ltd., which began consolidation from November 28, 2023[76]. - The company has extended the construction deadline for the Qizheng Tibetan Medicine Industrial Base project to December 31, 2023, with total investment of ¥332,014,897.54 during the reporting period[130]. - The cumulative actual investment in the Qizheng Tibetan Medicine Industrial Base project reached ¥835,456,266.17 by the end of the reporting period[130]. Recognition and Awards - The company was recognized as a "Key Leading Enterprise" in industrialization by multiple national authorities, highlighting its industry position[45]. - The company ranked 12th in the "Top 20 Most Influential Traditional Chinese Medicine Enterprises" at the SCO Traditional Medicine Industry Conference[45]. - The company has been recognized as a "National Innovative Enterprise" and a "National High-tech Enterprise," reflecting its commitment to innovation and technology[181]. - The company’s product "Qizheng Pain Relief Patch" received multiple awards, including "2023 Annual OTC Golden Product," highlighting its market recognition[181]. - The company received several accolades, including the "Engineering Technology Talent Contribution Award" from the China International Science Exchange Foundation[67]. Operational Efficiency - The company has optimized production processes to improve efficiency and ensure timely supply for multiple products[42]. - The company has established a digital supply chain system and is enhancing its digital marketing ecosystem to improve sales channels[47]. - The company has implemented a digital management system (MES) at its Linzhi factory to enhance production efficiency and quality control[55]. - The company has a complete supply, research and development, production, and sales system, ensuring operational efficiency[184]. Regulatory Compliance and Governance - The company has confirmed that there are no significant impacts on its financial statements from the implementation of new accounting standards effective January 1, 2023[171]. - The company has not reported any discrepancies between financial reports prepared under international accounting standards and those under Chinese accounting standards[172]. - The company has ensured that all board members attended the meeting to review the annual report, highlighting governance and accountability[152]. - The company has implemented new accounting policies to address previous financial discrepancies and ensure compliance with regulatory standards[199].